Article
Published 23 Jun 2026
FDA Expands TOFIDENCE® (Tocilizumab-bavi) Label To Include CRS And COVID-19
Goodwin Procter LLP
Your search returned 14,253 results
Refine Your Search
Search Results
- Relevance
- Newest
- Oldest
Article
Published 23 Jun 2026
SPC Manufacturing Waiver
J A Kemp LLP
Article
Published 23 Jun 2026
Royalty Monetization In An Era Of Drug Pricing Pressure: How The IRA Is Affecting Royalty Monetizations
Goodwin Procter LLP
Article
Published 23 Jun 2026
U.S. Supreme Court Weighs In On "Skinny Labels" And Inducement
Jones Day
Article
Published 23 Jun 2026
FDA Issues New Guidance For Submitting Patent Information For Listing In The “Orange Book”
WilmerHale
Article
Published 23 Jun 2026
CMS Proposes Permanent Framework For Medicare Drug Price Negotiation Program
Duane Morris LLP
Article
Published 22 Jun 2026
FDA’s Focus Returns To Compounding And Telehealth: Another Wave Of Warning Letters
Sheppard, Mullin, Richter & Hampton LLP
Article
Published 22 Jun 2026
New Jersey Cannabis Law: How The Sanders Decision Affects Employers
Jackson Lewis P.C.
Article
Published 22 Jun 2026
EPA Updates New Approach Methods To Replace Animal Testing For Chemical Assessments
Bergeson & Campbell
Article
Published 22 Jun 2026
What To Watch: Status Update On Peptide Regulation
Sheppard, Mullin, Richter & Hampton LLP
Article
Published 22 Jun 2026
FDA Just Added The First New Sunscreen Active Ingredient In Nearly 30 Years
Diaz Trade Law
Article
Published 19 Jun 2026
The Price Isn’t Right: Emerging Patchwork Of State Surveillance Pricing Bans Creates Compliance Complications For Businesses
Sheppard, Mullin, Richter & Hampton LLP
Article
Published 19 Jun 2026
FDA In Flux — June 2026 Newsletter
Mintz
Article
Published 19 Jun 2026
SPCs To Keep The CJEU Busy: Four Referrals To Watch
J A Kemp LLP
Article
Published 19 Jun 2026
FDA In Flux - June 2026
Mintz
Article
Published 19 Jun 2026
Evolving And Modernizing Pharmaceutical IP Portfolio Planning
Barnes & Thornburg LLP
Article
Published 18 Jun 2026
The Fillet, The "Whole" Fillet, And Nothing But The Fillet?
Global Advertising Lawyers Alliance (GALA)
Article
Published 18 Jun 2026
Alvotech’s BLA For Vedolizumab Biosimilar First To Be Accepted By FDA
Goodwin Procter LLP
Article
Published 18 Jun 2026
The Motion To Stay DEA’s Schedule III Rule: Strong Enough To Stick?
Harris Sliwoski
Article
Published 18 Jun 2026
Supreme Court Clarifies Induced Infringement Standard And Reinforces Skinny-Label Protection For Generic Drug Manufacturers
Lerner David